Bausch HealthBHC
BHC
About: Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Employees: 20,700
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 24
7% more funds holding
Funds holding: 208 [Q3] → 223 (+15) [Q4]
0.35% less ownership
Funds ownership: 69.27% [Q3] → 68.92% (-0.35%) [Q4]
4% less capital invested
Capital invested by funds: $2.08B [Q3] → $1.99B (-$84.6M) [Q4]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 7 (-1) [Q4]
30% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 74
58% less call options, than puts
Call options by funds: $37.8M | Put options by funds: $89.1M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
28%
upside
Avg. target
$9
44%
upside
High target
$10
60%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
Jefferies David Steinberg 0 / 0 met price target | 28%upside $8 | Hold Downgraded | 6 Feb 2025 |
RBC Capital Douglas Miehm 46% 1-year accuracy 11 / 24 met price target | 60%upside $10 | Sector Perform Maintained | 30 Jan 2025 |
Financial journalist opinion
Based on 10 articles about BHC published over the past 30 days
Negative
Reuters
5 days ago
Bausch + Lomb recalls some of its implantable eye lenses
Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.
Negative
Market Watch
5 days ago
Bausch + Lomb Recalls EnVista Intraocular Lenses
The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular lenses on its enVista platform.
Neutral
Accesswire
5 days ago
Bausch Health to Announce First Quarter Results on April 30
LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m.
Neutral
Business Wire
5 days ago
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) on its enVista platform. This action was taken out of an abundance of caution after the company received reports of complications, the cause of which could not immediately be explained. “As much as we believe in the enVista platform, patient safety will always be o.
Negative
Benzinga
6 days ago
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday.
Neutral
Accesswire
1 week ago
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering (the "Offering") of $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd. (the "Issuer"), a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.
Neutral
Accesswire
1 week ago
Bausch Health Announces Conditional Redemption of Senior Notes
LAVAL, QC / ACCESS Newswire / March 21, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that (i) it has delivered conditional notices of redemption for all of its outstanding 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 5.750% Senior Secured Notes due 2027 and 6.125% Senior Secured Notes due 2027 (collectively, the "BHC Notes") and (ii) 1375209 B.C. Ltd., the Company's indirect wholly-owned subsidiary ("HoldCo"), has delivered a conditional notice of redemption for all of its outstanding 9.000% Senior Secured Notes due 2028 (collectively with the BHC Notes, the "Notes").
Neutral
Accesswire
1 week ago
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched the syndication of new senior secured credit facilities totaling at least $3.8 billion. The new senior secured credit facilities are expected to consist of (i) a 5-year senior secured revolving credit facility in an amount of at least $400 million (the "New Revolving Facility") and (ii) a $3,400 million 5.5-year secured term loan B facility (the "New Term Loan Facility" and, together with the New Revolving Facility, the "New Senior Secured Credit Facilities") through its indirect wholly-owned subsidiary, 1261229 B.C.
Neutral
Accesswire
1 week ago
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched an offering (the "Offering") of $4.0 billion aggregate principal amount of new senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd., a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.
Neutral
Accesswire
2 weeks ago
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
LAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, today provided an update on its financing plans. The Company announced that it has engaged J.P.
Charts implemented using Lightweight Charts™